Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

DOI Web Site 被引用文献1件
  • Moshe Mittelman
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva 49100, Israel; Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; and Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
  • Drorit Neumann
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva 49100, Israel; Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; and Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
  • Alpha Peled
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva 49100, Israel; Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; and Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
  • Pazit Kanter
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva 49100, Israel; Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; and Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
  • Nechama Haran-Ghera
    Department of Medicine, Rabin Medical Center, Hasharon Hospital, Petach-Tikva 49100, Israel; Department of Cell Biology and Histology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel; and Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel

書誌事項

公開日
2001-04-17
DOI
  • 10.1073/pnas.081275298
公開者
Proceedings of the National Academy of Sciences

この論文をさがす

説明

<jats:p>Recombinant human erythropoietin (rHuEpo) has been used successfully in the treatment of cancer-related anemia. Clinical observations with several patients with multiple-myeloma treated with rHuEpo has shown, in addition to the improved quality of life, a longer survival than expected, considering the poor prognostic features of these patients. Based on these observations, we evaluated the potential biological effects of rHuEpo on the course of tumor progression by using murine myeloma models (MOPC-315-IgAλ<jats:sub>2</jats:sub>and 5T33 MM-IgG<jats:sub>2b</jats:sub>). Here we report that daily treatment of MOPC-315 tumor-bearing mice with rHuEpo for several weeks induced complete tumor regression in 30–60% of mice. All regressors that were rechallenged with tumor cells rejected tumor growth, and this resistance was tumor specific. The Epo-triggered therapeutic effect was shown to be attributed to a T cell-mediated mechanism. Serum Ig analysis indicated a reduction in MOPC-315 λ light chain in regressor mice. Intradermal inoculation of 5T33 MM tumor cells followed by Epo treatment induced tumor regression in 60% of mice. The common clinical manifestation of myeloma bone disease in patients with multiple-myeloma was established in these myeloma models. Epo administration to these tumor-bearing mice markedly prolonged their survival and reduced mortality. Therefore, erythropoietin seems to act as an antitumor therapeutic agent in addition to its red blood cell-stimulating activity.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ